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Abstract
BackgroundandobjectivesLarge studies on long-termkidneyoutcome inpatientswith anti-glomerular basement
membrane (anti-GBM) GN are lacking. This study aimed to identify clinical and histopathologic parameters that
predict kidney outcome in these patients.
Design, setting, participants,&measurementsThis retrospective analysis included a total of 123patientswith anti-
GBM GN between 1986 and 2015 from six centers worldwide. Their kidney biopsy samples were classified
according to the histopathologic classification forANCA-associatedGN.Clinical data such as details of treatment
were retrieved from clinical records. The primary outcome parameter was the occurrence of ESRD. Kidney
survival was analyzed using the log-rank test and Cox regression analyses.
ResultsThe 5-year kidney survival ratewas 34%,with an improved rate observed among patients diagnosed after
2007 (P=0.01). In patients with anti-GBM GN, histopathologic class and kidney survival were associated
(P,0.001). Only one of 15 patients with a focal class biopsy sample ($50% normal glomeruli) developed ESRD.
Patients with a sclerotic class biopsy sample ($50% globally sclerotic glomeruli) and patients with 100% cellular
crescentsdidnot recover fromdialysisdependencyatpresentation. Inmultivariableanalysis,dialysisdependency
at presentation (hazard ratio [HR], 3.17; 95% confidence interval [95% CI], 1.59 to 6.32), percentage of normal
glomeruli (HR, 0.97; 95% CI, 0.95 to 0.99), and extent of interstitial infiltrate (HR, 2.02; 95% CI, 1.17 to 3.50) were
predictors of ESRD during follow-up.
ConclusionsDialysis dependency, lowpercentage of normal glomeruli, and large extent of interstitial infiltrate are
associated with poor kidney outcome in anti-GBM GN. Kidney outcome has improved during recent years; the
success rate doubled after 2007.
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Introduction
Anti-glomerular basement membrane (anti-GBM) dis-
ease is an aggressive autoimmune disease (1), with an
estimated incidence of 1–2 cases per million popula-
tion per year (2). The disease affects glomerular
capillaries, which usually leads to rapidly progressive
GN, and pulmonary capillaries, possibly manifesting
as alveolar hemorrhage. Kidney disease predominates
in the majority of patients and is characterized by
glomerular fibrinoid necrosis and crescent formation
(3). To distinguish anti-GBM GN from other kidney
diseases, immunofluorescence appearances are deci-
sive, showing linear Ig deposits along the glomerular
basement membrane (GBM) (4). In most cases, these
deposits signify binding of circulating IgG autoanti-
bodies with the NC1 domain of the a-3 chain of type
IV collagen in the GBM (5,6). Anti-GBM autoanti-
bodies can be detected in the serum of most patients,
serving as a diagnostic tool. Besides anti-GBM anti-
body positivity, approximately one third of patients
have ANCA (3,7).
The discovery of anti-GBM antibodies and their
pathogenicity provide the rationale for treatment with
plasma exchange and immunosuppressive agents,
particularly cyclophosphamide and corticosteroids (8).
This therapy combined with better supportive care and
earlier diagnosis has improved the extremely poor
outcome of patients with anti-GBM GN over the past
decades (9–12). Despite these improvements, the rapid
deterioration caused by the disease still causes ESRD,
requiring dialysis at presentation in approximately 55%
of patients (9). At 1-year follow-up, reported kidney
survival rates range between 20% and 40% (10,12–15).
Kidney outcome has been correlated with the severity of
kidney failure at presentation and the percentage of
crescents on kidney biopsy (9,11–16).
In a landmark paper from 2001, patients with anti-
GBM GN who were dialysis dependent at presentation
and had 100% crescents on their kidney biopsy did not
recover kidney function (9). On the basis of this study,
the Kidney Disease: Improving Global Outcomes guide-




















































Albinusdreef 2, P.O. Box
9600, 2300 RC Leiden,
The Netherlands. Email:
e.e.van_daalen@lumc.nl
www.cjasn.org Vol 13 January, 2018 Copyright © 2018 by the American Society of Nephrology 63
with dialysis dependency and have 100% cellular crescents in
an adequate biopsy sample, and who are without lung
hemorrhage, can refrain from intensive treatment with
plasma exchange, corticosteroids, and cyclophosphamide
(17). However, a recent study suggested that all patients
with anti-GBM GN should receive intensive therapy be-
cause the combination of plasma exchange, corticosteroids,
and cyclophosphamide had a favorable effect even on
patients who presented with clinical and/or histologic
parameters indicative of a poor prognosis (11). In contrast,
another recent study found that oligo-anuric patients who
received intensive treatment and those who received minimal
treatment had similarly poor patient and kidney survival (16).
Because none of these patients recovered kidney function,
a kidney biopsy may not be essential for predicting the
prognosis of oligo-anuric patients (16).
Given the controversies regarding the predictive value of
the kidney biopsy and the utility of intensive therapy in
patients with anti-GBM GN, large studies on long-term
kidney outcome are highly warranted to further improve
patient-tailored therapy. Therefore, we investigated the
clinical and histopathologic predictors of long-term kidney




Patients were eligible for this study if they had a clinical
presentation compatible with anti-GBM GN in combina-
tion with positive (.1+) glomerular linear IgG staining on
immunofluorescence and/or positive serum anti-GBM
antibodies. Entry criterion for this study was the availabil-
ity of a kidney biopsy sample, which was collected from a
pathology department at one of the following centers: the
University of North Carolina at Chapel Hill (n=34); Impe-
rial College London (n=26); Addenbrooke’s Hospital, Cam-
bridge (n=25); LabPlus, Auckland (n=16); Leiden
University Medical Center (n=15); and University Medical
Center Utrecht (n=7). The cohort was divided according to
year of diagnosis from which we created three groups of
similar sizes in advance, which led to the following
categorization: 1986–2000, 2001–2006, and 2007–2015. Pa-
tients with double positivity for anti-GBM antibodies and
ANCA were included in the study, whereas patients with
any other coexisting kidney disease were excluded. This
study was conducted in accordance with the ethical
principles stated in the Declaration of Helsinki.
Biopsy Specimen Evaluation
A diagnostic kidney specimen was available for light
microscopic evaluation in 118 patients. Biopsy specimens
were evaluated independently by one of two experienced
nephropathologists (I.M.B. or J.C.J.) who were blinded to
the clinical data. The Berden classification for ANCA-
associated GN was used to score the biopsy samples; focal
class contained biopsy samples with $50% normal glo-
meruli, crescentic class contained biopsy samples with
$50% glomeruli with cellular crescents, sclerotic class
contained biopsy samples with $50% glomeruli with
global sclerosis, and the remaining biopsy samples were
designated as mixed class (18). Moreover, tubulointerstitial
parameters were evaluated; interstitial fibrosis and tubular
atrophy and interstitial infiltrate were scored semiquanti-
tatively (scale from 0 to 3), and tubulitis was scored as
absent or present (0 or 1). Kidney biopsy samples from five
patients could not be retrieved, but pathology reports had
sufficient information to classify the biopsy samples ac-
cording to the Berden classification, and medical files
comprised complete clinical data. Results from immuno-
fluorescence were assessed from the pathology report in all
patients.
Clinical Data
Clinical data were retrieved from medical records at the
participating centers. Kidney function at baseline (before
start of dialysis) was expressed as serum creatinine (mil-
ligrams per deciliter) and was classified as serum creatinine
,5.7 or $5.7 mg/dl as reported in previous studies
(9,12,16). Dialysis dependency at presentation was defined
as need for acute RRT during the first hospital admission.
The outcome of ESRD was defined as dialysis dependency
during follow-up or kidney transplantation. Kidney sur-
vival was expressed as time to ESRD, and patient survival
as time to death. Standard therapy was similar between
centers and consisted of plasma exchange (minimum of
seven exchanges or until anti-GBM antibodies were neg-
ative), oral and/or intravenous cyclophosphamide for 3–6
months, and oral and/or intravenous corticosteroids.
Missing data are reported in the legends of tables, and
percentages of the total of nonmissing data are presented.
Each analysis included patients with complete data on the
variable of interest.
Statistical Analyses
Continuous variables are expressed as means6SD or
medians (interquartile range), and were compared between
groups using the t test, one-way ANOVA, Mann–Whitney
U test, or Kruskal–Wallis H test, as appropriate. Categoric
variables are expressed as numbers (%), and differences
were assessed with the chi-squared test or chi-squared
trend test. Kidney and patient survival was analyzed using
the Kaplan–Meier method and log-rank test. Univariable
and multivariable Cox regression analyses were performed
to identify predictors of kidney survival. Results are
expressed as hazard ratio (HR) with 95% confidence
interval (95% CI). SPSS version 23 (IBM Corp., Armonk,
NY) was used for all analyses, and P values below 0.05
were considered statistically significant.
Results
Patient Characteristics
The characteristics of the total 123 patients are depicted
in Table 1. Males in the cohort (54%) were significantly
younger than females (47620 versus 55618 years; P=0.02).
Data on serology were available for 108 patients; 49% were
positive for anti-GBM antibodies only (“single positive”);
32% were positive for anti-GBM antibodies and ANCA
(“double positive”); 6% had detectable ANCA only; and
13% had no detectable anti-GBM antibodies or ANCA.
Double-positive patients were older than single-positive
patients (P=0.003; Table 2). Patients who had negative
serology test results were significantly younger compared
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with patients with positive serology test results (i.e., anti-
GBM antibody and/or ANCA positivity) (P=0.02; Supple-
mental Table 1). Median duration of follow-up was 3.9
(1.3–6.1) years. Five patients were lost to follow-up within
1 year. The 5-year kidney survival rate was 34%, and the 5-
year patient survival rate was 83%. Kidney survival at 5
years was 50% in patients who were diagnosed after 2007
(Figure 1).
Evaluation of Diagnostic Renal Biopsy Specimens
Immunofluorescence was performed successfully in 117
patients and was positive for linear IgG in all of them; six
specimens for immunofluorescence did not contain assess-
able glomeruli. Ten biopsy samples were classified as
sclerotic class, 15 biopsy samples as focal class, 72 biopsy
samples as crescentic class, and the remaining 26 biopsy
samples as mixed class (Table 3). The focal group had a
younger mean age than the other three classes together
(41619 versus 52619 years; P=0.03). Serum anti-GBM
antibodies were more frequently detected in patients
from the crescentic class than in those from the other
classes. All patients from the sclerotic class who were
positive for anti-GBM antibodies and who were tested for
ANCA showed double positivity for both antibodies. The
amount of interstitial fibrosis and tubular atrophy differed
significantly between classes, but the extent of interstitial
infiltrate did not (Table 4). Double-positive patients tended
to have a higher percentage of sclerotic glomeruli and a
higher interstitial fibrosis and tubular atrophy score com-
pared with single-positive patients (P=0.07 for both param-
eters; Table 2). The minimum number of glomeruli was
set at six in this study, whereas the Berden classification
set a minimum of ten glomeruli. The predictive value of
glomerular lesions was greater in biopsy samples with ten
or more glomeruli (n=101) compared with biopsy samples
with 6–10 glomeruli (n=22). However, including biopsy









Age, yr 51619 54619 46621 53617
Males 66 (54) 22 (54) 24 (63) 20 (46)
Anti-GBM antibodies positivea 92 (82) 31 (87) 28 (78) 33 (81)
Anti-GBM antibodies, ANCA negative 53 (60) 12 (44) 20 (71) 21 (64)
Anti-GBM antibodies, ANCA positive 35 (40) 15 (56) 8 (27) 12 (36)
ANCA typeb
Anti-MPO 23 (85) 9 (90) 7 (100) 7 (70)
Anti-PR3 4 (15) 1 (10) 0 (0) 3 (30)
Lung involvementc 41 (35) 14 (37) 12 (33) 15 (35)
Serum creatinine, mg/dld 7.0 (3.5–10.3) 9.0 (5.8–13.9) 7.3 (4.5–11.4) 4.6 (1.9–7.0)
Dialysis dependentd 69 (56) 28 (68) 27 (71) 14 (32)
Follow-up (n=123)
Duration of follow-up, yrd 4.664.0 5.365.1 5.963.5 2.862.2
ESRD at end of follow-upe 82 (67) 31 (76) 29 (76) 22 (50)
Transplantation 32 (26) 9 (22) 15 (40) 8 (18)
Deathe 34 (28) 17 (42) 11 (29) 6 (14)
Treatment (n=110)
Plasma exchange 91 (83) 24 (71) 31 (89) 38 (88)
Median number of exchanges 7 (6–12) 6 (5–10) 10 (7–10) 7 (6–14)
Cyclophosphamidee 88 (80) 21 (62) 29 (88) 38 (88)
Oralf 43 (60) 13 (68) 14 (67) 16 (50)
Intravenousf 25 (35) 6 (32) 6 (28) 13 (41)
Both 4 (5) 0 (0) 1 (5) 3 (9)
Corticosteroids 106 (96) 33 (94) 32 (97) 42 (98)
Azathioprine 21 (19) 5 (15) 6 (18) 10 (23)
Mycophenolate mofetil 12 (11) 4 (12) 4 (12) 4 (9)
Rituximabd 10 (9) 0 (0) 0 (0) 10 (23)
Data are presented as numbers (%), means6SD, or medians (interquartile range). GBM, glomerular basement membrane; MPO,
myeloperoxidase; PR3, proteinase 3.
aResults from anti-GBMantibody ELISAwere available in 112 patients. Results fromANCAELISAwere available in 114 patients. Both
tests were performed in 108 patients; four patients with positivity for anti-GBMantibodies had no available results fromANCAELISA.
bThirty-five patients were anti-GBM antibodies and ANCA positive. Of these, ANCA type (anti-MPO or anti-PR3) was known in 27
patients.
cTotal, n=117 patients.
dDifferent between subgroups with P value ,0.001.
eDifferent between subgroups with P value ,0.05.
fRoute of administration of cyclophosphamidewas known for 72 patients. Themean oral cyclophosphamide dose at the start of therapy
was 118649 g (n=30), and the mean intravenous dose was 11136460 g (n=8).
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samples with 6–10 glomeruli did not change the predictive
value of the glomerular lesions (Supplemental Table 2);
therefore, they were included. No differences in treatment
were observed between histopathologic classes, except for
cyclophosphamide; patients from the focal and mixed class
received cyclophosphamide more frequently than patients
from the crescentic and sclerotic class (Table 5).
Kidney Function According to Histopathologic Class
Kidney function at baseline in terms of serum creatinine
was significantly better in the focal class compared with the
other three classes (Table 3). No patient from the focal class
required dialysis at presentation, and only one developed
ESRD during follow-up (Figure 2). Most patients (90%)
from the sclerotic class developed ESRD at some time point,
whereas the outcome in crescentic and mixed classes was
more variable (Figures 2 and 3A). When patients were catego-
rized according to the percentage of normal glomeruli, kidney
survival decreased with each lower percentage category of
normal glomeruli (Figure 3B). Patient survival did not differ
between histopathologic classes (Figure 3C).
Predictors of ESRD
In Kaplan–Meier analysis, double-positive patients had a
similar kidney survival to single-positive patients (P=0.75;
Supplemental Figure 1A). Kidney survival was also similar
in patients with negative and positive serology (P=0.69;
Supplemental Figure 1B). Age, serum creatinine level,
dialysis dependency at presentation, histopathologic clas-
sification, percentage of normal glomeruli, percentage of
cellular crescents, extent of interstitial fibrosis and tubular
atrophy, and extent of interstitial infiltrate were associated
with ESRD in univariable Cox regression analyses (Table 6).
Dialysis dependency at presentation was a discontinuous
variable that predicted ESRD most significantly. Therefore,
each parameter that was significant in univariable analysis
was evaluated separately in a multivariable Cox regression
analysis that included dialysis dependency at presentation.






Age, yr 47619 59617 0.003
Males 27 (51) 19 (54) 0.76
Lung involvementb 15 (28) 13 (39) 0.29
Serum creatinine at presentation, mg/dl 7.2 (3.5–10.0) 7.2 (3.9–10.1) 0.92
Dialysis dependent at presentation 32 (60) 20 (57) 0.76
Year of diagnosis 0.11
1986–2000 12 (23) 15 (43)
2001–2006 20 (38) 8 (23)
2007–2015 21 (39) 12 (34)
ESRD at end of follow-up 36 (68) 25 (71) 0.73
Histopathologic class 0.03
Focal 7 (13) 4 (11)
Crescentic 37 (70) 18 (51)
Mixed 9 (17) 8 (23)
Sclerotic 0 (0) 5 (14)
Normal glomeruli, percentagec 0 (0–26) 0 (0–13) 0.40
Cellular crescents, percentagec 61632 58632 0.63
Sclerotic glomeruli, percentagec 2 (0–16) 13 (0–28) 0.07
Interstitial fibrosis and tubular atrophyc 0.07
0–1 36 (72) 18 (53)
2–3 14 (28) 16 (47)
Interstitial infiltratec 0.10
0–1 22 (44) 9 (27)
2–3 28 (56) 25 (73)
Tubulitisc 0.20
0 18 (36) 17 (50)
1 32 (64) 17 (50)
Intensive treatmentd 34 (71) 14 (45) 0.02
Maintenance therapy with azathioprine
or mycophenolate mofetile
7 (14) 13 (38) 0.01
Data are presented as numbers (%), means6SD, or medians (interquartile range).
aSingle-positive patients were positive for serum anti-glomerular basementmembrane (anti-GBM) antibodies and negative for ANCA.
Double-positive patients were positive for anti-GBM antibodies and positive for ANCA.
bTotal, n=86 patients.
cTotal, n=84 patients.
dIntensive treatment consisted of at least seven plasma exchanges, corticosteroids, and cyclophosphamide, mycophenolate mofetil, or
rituximab. Excluding patients without intensive treatment and relatively preserved renal function at presentation. Total, n=79 patients.
eThe minimal duration of maintenance therapy was 3 months. Total, n=84 patients.
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The percentage of normal glomeruli and the extent of
interstitial infiltrate remained significant predictors of ESRD
in multivariable analysis. A multivariable analysis,
including dialysis dependency, percentage of normal glo-
meruli, and extent of interstitial infiltrate, showed that
these parameters predicted ESRD independently (Table 6).
Figure 1. | The kidney survival is highest in patients who were diagnosed between 2007 and 2015.
Table 3. Characteristics stratified by histopathologic class: Baseline and follow-up characteristics
Characteristic Focal (n=15) Crescentic (n=72) Mixed (n=26) Sclerotic (n=10) P Value
Age, yr 41619 53619 53616 50625 0.17
Males 9 (60) 41 (57) 10 (39) 6 (60) 0.37
Anti-GBM antibodies
positivea
11 (79) 58 (91) 17 (71) 6 (60) 0.02
Anti-GBM antibodies,
ANCA negative
7 (64) 37 (67) 9 (53) 0 (0) 0.03
Anti-GBM antibodies,
ANCA positive
4 (36) 18 (33) 8 (47) 5 (100)
ANCA typeb 0.001
Anti-MPO 0 (0) 14 (100) 7 (87) 2 (100)
Anti-PR3 3 (100) 0 (0) 1 (13) 0 (0)
Lung involvementc 7 (50) 26 (37) 4 (16) 4 (57) 0.06
Serum creatinine at
presentation, mg/dl
1.4 (1.0–1.7) 7.8 (6.4–12.6) 4.2 (2.6–7.2) 6.6 (4.5–15.2) ,0.001
Dialysis dependent at
presentation
0 (0) 51 (71) 10 (39) 8 (80) ,0.001
Year of diagnosis
1986–2000 3 (20) 28 (39) 4 (15) 6 (60) ,0.01
2001–2006 2 (13) 26 (36) 8 (31) 2 (20)
2007–2015 10 (67) 18 (25) 14 (54) 2 (20)
Duration of follow-up, yr 4.763.7 4.964.2 4.363.8 3.463.6 0.72
ESRD at end of follow-up 1 (7) 57 (79) 15 (58) 9 (90) ,0.001
Transplantation 0 (0) 25 (35) 4 (15) 3 (30) 0.01
Death 2 (13) 24 (33) 5 (19) 3 (30) 0.32
Data are number (%),mean6SD, ormedian (interquartile range). GBM, glomerular basementmembrane;MPO,myeloperoxidase; PR3,
proteinase 3.
aResults from anti-GBMantibody ELISAwere available in 112 patients. Results fromANCAELISAwere available in 114 patients. Both
tests were performed in 108 patients.
bThirty-five patients were anti-GBM antibodies and ANCA positive. Of these, ANCA type (anti-MPO or anti-PR3) was known in 27
patients.
cTotal, n=117 patients.
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Treatment
Data on therapy were complete for 110 patients. In-
tensive treatment consisting of at least seven plasma
exchanges (19), corticosteroids, and cyclophosphamide,
mycophenolate mofetil, or rituximab was given to 61
patients. Of the 49 remaining patients, 25 patients were
treated with plasma exchange but not with cyclophospha-
mide and 24 with cyclophosphamide but no or less than
seven plasma exchanges. Five of these 49 patients had
relatively preserved kidney function at presentation (serum
creatinine#1.4 mg/dl); therefore, they were not included in
the analysis comparing intensive versus mild treatment
(Supplemental Table 3). Older patients, double-positive
patients, and patients with severe kidney failure at
presentation were less likely to receive intensive treatment.
Moreover, patients with a lower percentage of normal
glomeruli and a higher percentage of crescentic glomeruli
were treated less intensively. Over time, there was a
significant trend toward increased use of an intensive
treatment regimen (Supplemental Table 3). Twenty-one
patients received azathioprine, and 12 patients received
mycophenolate mofetil for induction and/or remission
therapy. Double-positive patients received maintenance
therapy with azathioprine or mycophenolate mofetil more
frequently than single-positive patients (Table 2). Ten
patients were treated with rituximab; nine of these patients
also received cyclophosphamide concurrently or before
treatment with rituximab.










22612 1769 1969 1969 0.35
Normal glomeruli,
percentage
71 (62–90) 0 (0–8) 9 (0–31) 0 (0–0) ,0.001
Cellular crescents,
percentage
12610 81616 32615 19616 ,0.001
Sclerotic glomeruli,
percentage




0 8 (53) 16 (24) 1 (4) 0 (0)
1 7 (47) 30 (44) 11 (44) 1 (10)
2 0 (0) 19 (28) 10 (40) 3 (30)
3 0 (0) 3 (4) 3 (12) 6 (60)
Interstitial infiltrate 0.16
0 5 (33) 5 (8) 1 (4) 1 (10)
1 9 (60) 17 (25) 12 (48) 2 (20)
2 1 (7) 22 (32) 6 (24) 7 (70)
3 0 (0) 24 (35) 6 (24) 0 (0)
Tubulitis 0.02
0 12 (80) 27 (40) 15 (60) 6 (60)
1 3 (20) 41 (60) 10 (40) 4 (40)
Data arenumber (%),mean6SD,ormedian (interquartile range). Excludingfivepatientswithoutkidneybiopsysamplesavailable for re-
evaluation. Total, n=118 patients.








Intensive treatmenta 8 (57) 33 (51) 16 (70) 4 (50) 0.46
Plasma exchange 12 (86) 53 (82) 21 (91) 5 (63) 0.32
Cyclophosphamide 13 (93) 46 (71) 23 (100) 6 (75) ,0.01
Corticosteroids 14 (100) 62 (95) 23 (100) 7 (88) 0.33
Azathioprine 4 (29) 8 (12) 6 (26) 3 (38) 0.11
Mycophenolate
mofetil
2 (14) 7 (11) 2 (9) 1 (13) 0.92
Rituximab 3 (21) 3 (5) 4 (17) 0 (0) 0.06
Data are number (%), mean6SD, or median (interquartile range). Total, n=110 patients.
aIntensive treatment was defined as treatment consisting of at least seven plasma exchanges, corticosteroids, and cyclophosphamide,
mycophenolate mofetil or rituximab.
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Discussion
In one of the largest studies to date, we investigated the
long-term outcome of 123 patients with anti-GBMGN from
six centers worldwide. We analyzed the predictive value
of the kidney biopsy in anti-GBM GN by applying the
histopathologic classification for ANCA-associated GN
(18). The histopathologic classification was a significant
predictor of kidney survival in univariable analysis, but not
in multivariable analysis including dialysis dependency at
presentation. However, the percentage of normal glomeruli
and the extent of interstitial infiltrate remained significant
predictors in multivariable analysis. We also found that
patients with $50% globally sclerotic glomeruli did not
recover from the need for acute dialysis. The crescentic and
mixed classes, as defined for ANCA-associated GN,
seemed less important in predicting the outcome of anti-
GBM GN because their kidney outcome was variable. In
line with the study by Levy et al. (9), we found that patients
who were dialysis dependent at presentation and had 100%
cellular crescents at biopsy did not recover kidney function.
Age seemed to be an important denominator in determin-
ing the therapeutic strategy and in outcome. Younger patients
more often had a focal class biopsy specimen, weremore likely
to stay dialysis independent, and received intensive treatment
more frequently. However, whenwe performedmultivariable
analyses, age was no longer significantly associated with
ESRD. From our data, we can conclude that histopathologic
parameters, i.e., percentage of normal glomeruli and extent of
interstitial infiltrate, are more predictive of outcome. Never-
theless, we feel that it is important to take age into account
when defining the optimal individual treatment strategy.
Interestingly, older age and double positivity were signifi-
cantly associated, but double positivity was not associated
with a worse outcome compared with single positivity.
The 5-year kidney survival rate in this study was 34%,
which is higher than reported by Cui et al. (11), but in line
with results from Levy et al. (9). Patients who were diagnosed
after 2007 had a two-fold higher kidney survival rate
compared with patients who were diagnosed before 2007.
Interestingly, most patients with a focal class biopsy sample
were diagnosed recently (2007–2015), suggesting earlier de-
tection of the disease or increased awareness of the hetero-
geneity of the disease (20,21). The favorable outcome of this
focal group can partially explain the observation of improved
kidney outcome since 2007. The other contributing factor to
this improvement is possibly the significant trend toward
increased use of intensive therapy. From 1986 to 2000, 36% of
the patients received intensive therapy, whereas 64% of the
patients diagnosed after 2007 were treated intensively.
The heterogeneity of anti-GBM disease has recently been
described by Nasr et al. (21) They described an atypic
variant of anti-GBM disease, characterized by linear GBM
staining for Igs, negative serum anti-GBM antibodies,
absence of a crescentic phenotype, mild renal insufficiency,
and absence of pulmonary hemorrhage. In our study, 20
patients had linear IgG deposits, but no detectable serum
anti-GBM antibodies; three of them fulfilled the description
of atypic anti-GBM disease. Therefore, the group of
patients without detectable serum anti-GBM antibodies,
but with linear IgG deposits, is rather heterogeneous.
Figure 2. | The flowchart shows a favorable outcome in the focal class, a poor outcome in the sclerotic class, and variable outcomes in the
mixed and crescentic class.
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Forty-five percent of our patients did not receive intensive
treatment and the reason for refraining from intensive
therapy was not always reported. However, some medical
reports stated that treatment was withdrawn because of the
results of kidney biopsy (i.e., a high percentage of affected
glomeruli), therapy-related complications such as serious
infections, or lack of improvement under therapy. Five
patients who did not receive intensive treatment presented
with relatively preserved kidney function, which was prob-
ably the reason for not initiating the full treatment regimen.
Our data suggest that patients who are dialysis dependent at
presentation and have either $50% globally sclerotic
glomeruli or 100% cellular crescents do not benefit
from intensive therapy and could therefore avoid the
risk of immunosuppression and follow a conservative
regimen. Other patients, including those with alveolar
hemorrhage, should be treated intensively.
In our cohort, ten patients were treated with rituximab.
In one center, rituximab along with cyclophosphamide has
become standard therapy in patients who are double positive
for anti-GBM antibodies and ANCA. Other indications for
rituximab were found in three patients. In one patient, the
kidney biopsy specimen showed a large infiltrate of CD20
positive B cells, providing a rationale to start anti-CD20 therapy
(i.e., rituximab). Another patient did not tolerate azathioprine;
therefore, rituximab was given instead. A third patient received
Figure 3. | Kidney survival is highest in patients with a focal class biopsy, and patient survival is similar in all histopathological classes. (A)
Kidney survival according to histopathologic class. (B) Kidney survival according to percentage of normal glomeruli. (C) Patient survival
according to histopathologic class.
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Table 6. Prognostic significance of clinical and histopathologic parameters on ESRD
Variable
Univariable Analysis Multivariable Analysisa Multivariable Analysisb
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age, yr 1.02 (1.01 to 1.03) ,0.01 1.01 (1.00 to 1.03) 0.06
Males 1.19 (0.77 to 1.84) 0.44
Lung involvement 1.19 (0.75 to 1.88) 0.47




4.83 (2.75 to 8.47) ,0.001 1.98 (0.96 to 4.10) 0.07
Dialysis dependency at
presentation
6.50 (3.68 to 11.47) ,0.001 a a 3.2 (1.6 to 6.3) 0.001
Histopathologic classification ,0.01 0.15
Focal (reference)
Crescentic 20.29 (2.80 to 147.26) 8.38 (1.10 to 63.87)
Mixed 11.67 (1.54 to 88.47) 6.77 (0.87 to 52.65)
Sclerotic 25.72 (3.24 to 204.51) 11.17 (1.34 to 3.13)
Percentage normal
glomeruli
0.95 (0.93 to 0.98) ,0.001 0.97 (0.95 to 0.99) ,0.01 0.97 (0.95 to 0.99) 0.01
Percentage cellular
crescents
1.02 (1.01 to 1.02) ,0.001 1.02 (1.00 to 1.05) 0.09
Percentage globally
Sclerotic glomeruli




1.88 (1.20 to 2.95) ,0.01 1.38 (0.87 to 2.18) 0.17
Interstitial infiltrate,
score 2–3
2.35 (1.44 to 3.83) 0.001 1.90 (1.16 to 3.13) 0.01 2.02 (1.2 to 3.5) 0.01
Tubulitis, present 1.51 (0.96 to 2.35) 0.07
HR, hazard ratio; 95% CI, 95% confidence interval.
aEach parameter that was significant in univariable analysis, was analyzed in a multivariable analysis including dialysis dependency at presentation. Dialysis dependency at presentation
remained significant in each multivariable analysis with P values #0.002.


















































rituximab, because the side-effects of cyclophosphamide
were likely to cause problems. Because only nine patients
were treated with rituximab and cyclophosphamide, con-
clusions on the response to rituximab could not be drawn.
This study included 123 patients with anti-GBM GN and
is therefore the largest study evaluating kidney biopsy
samples in relation to clinical outcome in this rare disease.
Another strength of the study is the relatively long duration
of follow-up (median 3.9 years). We consider the possibility
of the development of ESRD after the last date of follow-up
unlikely, because progression to ESRD usually occurs in the
initial phase of this disease (9). Because of the rapid onset of
anti-GBM disease, patient or referral delay have probably
not influenced our findings. A limitation of the study is the
possibility of selection bias; we only included patients with a
diagnostic kidney biopsy performed, thereby excluding pa-
tients with a contraindication for a kidney biopsy (e.g., frail
patients). Moreover, treatment was a potential confounder in
our study; therefore, we have investigated treatment in detail.
Future studies on histopathology in anti-GBM GN with
patients who are treated similarly are highly warranted.
In summary, dialysis independency at presentation, a
high percentage of normal glomeruli, and a lower extent of
interstitial infiltrate are associated with a favorable outcome
in patients with anti-GBM GN. Dialysis-dependent patients
with 100% cellular crescents or $50% sclerotic glomeruli are
very unlikely to recover, and may be refrained from intensive
therapy. Kidney survival has improved during recent years,
doubling the success rate after 2007. This is possibly the result
of earlier detection accompanied by the increased use of
intensive therapy in anti-GBM GN.
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